No­var­tis is ax­ing 150 ear­ly dis­cov­ery jobs as CNI­BR shifts fo­cus to the de­vel­op­ment side of R&D

4 weeks ago
R&D

Karuna clears PhII hur­dle in schiz­o­phre­nia, takes aim at a piv­otal in block­buster hunt — shares soar

4 weeks ago
R&D

FTC clears Bris­tol-My­ers’ $74B deal to buy Cel­gene — but Dems sig­nal a po­ten­tial hard shift against Big Phar­ma M&A

4 weeks ago
Pharma

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

4 weeks ago
R&D

Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

4 weeks ago
Deals
R&D

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares wilt

4 weeks ago
R&D

In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

4 weeks ago
China
Regulatory

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA weighs in for­mal­ly

4 weeks ago
Regulatory

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

4 weeks ago
R&D

FDA pan­el large­ly op­pos­es ex­pand­ing use of Lil­ly, Boehringer's SGLT2 in­hibitor to type 1 di­a­bet­ics

4 weeks ago
Pharma
R&D

Bay­er bets up to $100M on ex­plor­ing new bio­mol­e­c­u­lar con­den­sate ter­rain with a biotech up­start

4 weeks ago
R&D

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

4 weeks ago
R&D

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

4 weeks ago
Deals
R&D

Mer­ck shut­ters French re­search site in a re­or­ga­ni­za­tion aimed at elim­i­nat­ing more than 200 jobs

4 weeks ago
Pharma

Cel­gene ex­ecs shell out $92M cash for a pair of R&D deals that will fit per­fect­ly in their new home at Bris­tol-My­ers

4 weeks ago
R&D

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

4 weeks ago
R&D

Kad­mon wax­es rhap­sod­ic on cGVHD re­sults as race with Jakafi heats up

4 weeks ago
R&D

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

4 weeks ago
Cell/Gene Tx
R&D

The lat­est Cin­derel­la sto­ry in on­col­o­gy ends with a sud­den rout as up­dat­ed da­ta dis­play spooks in­vestors

5 weeks ago
R&D

Roche's SMA chal­lenge to Bio­gen's Spin­raza fran­chise looms larg­er with piv­otal win

5 weeks ago
R&D

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

5 weeks ago
People
R&D

As­traZeneca, Fi­bro­Gen flag ap­peal­ing pooled safe­ty da­ta on roxa for key seg­ment of the CKD mar­ket

Last month
R&D

An­ces­tryD­NA chief takes on liq­uid biop­sy chal­lenge; Thomas Lynch chairs for­mer col­league's can­cer start­up

Last month
Peer Review

Anap­tys­Bio gives in­vestors a rash as its big bet on eczema fails, sink­ing stock

Last month
R&D
First page Previous page 123456 Next page Last page